Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: The response to antipsychotics in patients with schizophrenia is still unsatisfactory. Therefore, augmentation with other antipsychotics is common in clinical situations. The purpose of this study was to evaluate the improvement of psychiatric symptoms and side effects after amisulpride add-on therapy. Methods: Forty patients with schizophrenia or schizoaffective disorder without treatment response to second-generation antipsychotics were included in this study. Psychotic symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS) and the Korean version of Calgary Depression Scale for Schizophrenia (CDSS) at baseline, 4 weeks, and 8 weeks after the addition of amisulpride. Results: Among the 29 subjects who completed the 8-week study, 34.5% were responders according to PANSS total score. At week 8, the mean positive (p ＜ 0.001), negative (p ＜ 0.001), general (p ＜ 0.001), and total (p ＜ 0.001) PANSS scores and CDSS scores (p = 0.002) showed significant improvement compared to baseline. There was no increase in extrapyramidal side effects according to Simpson Angus Scale (p = 0.379) and Barnes Akathisia Rating Scale (p = 0.070) and no weight gain (p = 0.308) after the add-on treatment. Conclusion: The addition of amisulpride for schizophrenia patients without therapeutic response to second-generation antipsychotics is considered an effective and safe treatment. This study's results suggested that augmentation of second- generation antipsychotics with amisulpride could be a useful option for patients with schizophrenia unresponsive to second-generation antipsychotics. Further studies investigating the efficacy of amisulpride add-on therapy using placebo control are necessary to confirm these results.
Abstract
Objective: The response to antipsychotics in patients with schizophrenia is still unsatisfactory. Therefore, augmentation with other antipsychotics is common in clinical situations. The purpose of this study was to evaluate the improvement of psychiatric symptoms and side effects after amisulpride add-on therapy. Methods: Forty patients with schizophrenia or schizoaffective disorder without treatment response to second-generation antipsychotics were included in this study. Psychotic symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS) and the Korean version of Calgary Depression Scale for Schizophrenia (CDSS) at baseline, 4 weeks, and 8 weeks after the addition of amisulpride. Results: Among the 29 subjects who completed the 8-week study, 34.5% were responders according to PANSS total score. At week 8, the mean positive (p ＜ 0.001), negative (p ＜ 0.001), general (p ＜ 0.001), and total (p ＜ 0.001) PANSS scores and CDSS scores (p = 0.002) showed significant improvement compared to baseline. There was no increase in extrapyramidal side effects according to Simpson Angus Scale (p = 0.379) and Barnes Akathisia Rating Scale (p = 0.070) and no weight gain (p = 0.308) after the add-on treatment. Conclusion: The addition of amisulpride for schizophrenia patients without therapeutic response to second-generation antipsychotics is considered an effective and safe treatment. This study's results suggested that augmentation of second- generation antipsychotics with amisulpride could be a useful option for patients with schizophrenia unresponsive to second-generation antipsychotics. Further studies investigating the efficacy of amisulpride add-on therapy using placebo control are necessary to confirm these results.
참고문헌 (27)
- Menezes NM, "A systematic review of longitudinal outcome studies of first-episode psychosis", Psychol Med, 36, pp.1349~1362 (2006)
- Lally J, "Antipsychotic medication in schizophrenia : a review", Br Med Bull, 114, pp.169~179 (2015)
- Srisurapanont M, "Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia : a systematic review and meta-analysis of randomized-controlled trials", J Psychiatr Res, 62, pp.38~47 (2015)
- Paton C, "Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine : a meta-analysis", J Clin Psychopharmacol, 27, pp.198~204 (2007)
- Hatta K, "Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia", Asian J Psychiat, 40, pp.82~87 (2019)
- Galling B, "Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and metaregression analysis", World Psychiatry, 16, pp.77~89 (2017)
- Puech A, "Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia:a dose-ranging study vs. haloperidol. The Amisulpride Study Group", Acta Psychiatr Scand, 98, pp.65~72 (1998)
- Möller HJ, "Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group", Psychopharmacology(Berl), 132, pp.396~401 (1997)
- Mortimer A, "A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia", Int Clin Psychopharmacol, 19, pp.63~69 (2004)
- Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
- Toledo-Romero F, "Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy", Pharmacopsychiatry, 48, pp.51~57 (2015)
- Molina JD, "Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine", Pharmacopsychiatry, 44, pp.142~147 (2011)
- Lerner V, "Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy", Clin Neuropharmacol, 28, pp.66~71 (2005)
- Barnes TR, "Amisulpride augmentation in clozapine-unresponsive schizophrenia(AMICUS) : a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness", Health Technol Assess, 21, pp.1~56 (2017)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders(DSM-5Ⓡ)" (2013), American Psychiatric Publishing
- Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Guy W, "ECDEU assessment manual for psychopharmacology" (1976), U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs
- 김용구, "한국어판 정신분열병의 캘거리 우울증 척도의 신뢰도 및 타당도 연구", 신경정신의학, 44(4), pp.446~455 (2005), 대한신경정신의학회
- Addington D, "Assessing depression in schizophrenia: the Calgary Depression Scale", Br J Psychiatry Suppl, (22), pp.39~44 (1993)
- Barnes TR, "A rating scale for drug-induced akathisia", Br J Psychiatry, 154, pp.672~676 (1989)
- Simpson GM, "A rating scale for extrapyramidal side effects", Acta Psychiatr Scand Suppl, 45(S212), pp.11~19 (1970)
- Leucht S, "Definitions of response and remission in schizophrenia : recommendations for their use and their presentation", Acta Psychiatr Scand Suppl, (438), pp.7~14 (2009)
- Lehman AF, "Practice guideline for the treatment of patients with schizophrenia", Am J Psychiatry, 161(2Suppl), pp.1~56 (2004)
- Tiihonen J, "Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia", JAMA Psychiatry, 76, pp.499~507 (2019)
- "Practice guideline for the treatment of patients with schizophrenia"[URL]
- Lee SJ, "A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400mg", day versus 800 mg, Clin Drug Investig, pp.2012, 32[DOI]
- Kahn RS, "Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder(OPTiMiSE) : a three-phase switching study", Lancet Psychiatry, 5, pp.797~807 (2018)